An abstract of ASCO2024

2024.05.24

An abstract of the American Society of Clinical Oncology (ASCO2024) presentation on 64Cu-ATSM (LM001), a radiotherapeutic agent for the treatment of malignant brain tumors that has been developed in collaboration with the National Cancer Center and Kanagawa Prefectural Cancer Center, has been published as a new treatment for malignant brain tumors.

Latest posts

2024.08.23
LinqMed received the “University Venture Award Special Prize” at the University Venture Award 2024
2024.05.24
An abstract of ASCO2024
2024.02.14
LinqMed was featured in Yomiuri Shimbun Online
2023.12.22
Announcement of selection for NEDO “The Deep-Tech Startup Support Fund/Deep-Tech Startup Support Program”
2023.12.22
LinqMed Announces Series A and additional Financing
2023.12.22
LinqMed and PeptiDream Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM in Japan
2023.11.15
Article published in the Japan Economic Research Institute “JERI Monthly Report”
2023.03.22
Received Venture Club Chiba 39th Business Plan Presentation Business Challenge Contest to Support Tomorrow’s Chiba Grand Award
2023.01.30
7th National Research and Development Agency Innovation Strategy Conference Panelist
2023.01.27
Mirai X (mirai cross) 2023 Category Grand Prize and GAP Grant Award

Latest posts

LinqMed received the “University Venture Award Special Prize” at the University Venture Award 2024

An abstract of ASCO2024

LinqMed was featured in Yomiuri Shimbun Online

Announcement of selection for NEDO “The Deep-Tech Startup Support Fund/Deep-Tech Startup Support Program”

LinqMed Announces Series A and additional Financing

LinqMed and PeptiDream Announce Strategic Partnership for the Development and Commercialization of 64Cu-ATSM in Japan

Article published in the Japan Economic Research Institute “JERI Monthly Report”

Received Venture Club Chiba 39th Business Plan Presentation Business Challenge Contest to Support Tomorrow’s Chiba Grand Award

7th National Research and Development Agency Innovation Strategy Conference Panelist

Mirai X (mirai cross) 2023 Category Grand Prize and GAP Grant Award